
    
      This is a Phase 1b, open-label, study design that will examine safety, tolerability, and
      maximum tolerated dose of tivozanib (AV-951) and FOLFOX6 in advanced colorectal cancer and
      other gastrointestinal cancers. In the study, only the doses of tivozanib (AV-951) will be
      escalated from 0.5 mg/day to 1.5 mg/day. All subjects will receive standard doses of FOLFOX6
      chemotherapy every 2 weeks.
    
  